THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH Patent applications |
Patent application number | Title | Published |
20150273051 | Improved Human Herpesvirus Immunotherapy - An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens. | 10-01-2015 |
20120115775 | MUTANT TAT PROTEINS AND USES THEREOF - Disclosed are viral proteins associated with Human Immunodeficiency Virus (HIV) infections and mutants thereof, particularly, mutant Tat proteins capable of modulating multiple steps of the HIV-1 replication cycle. Also provided are methods of using the mutant Tat proteins, and pharmaceutical compositions comprising the same, for prevention and treatment of HIV-1 infections, and/or symptoms associated therewith. | 05-10-2012 |
20110280899 | Novel Immunogenic Lipopeptides Comprising T-Helper And Cytotoxic T-Lymphocyte (CTL) Epitopes - The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope. | 11-17-2011 |
20110158998 | HELMINTH ANTIGEN AND IMMUNOTHERAPY - A helminth protein immunogen is described. Included as the immunogen is an isolated protein comprising an immunogenic, extracellular fragment of a schistosome tegument protein selected from the group consisting of a TSP-1 protein; a TSP-2 protein; and a 7TM protein. An antibody which binds the isolated protein is also described. Additionally, an immunotherapeutic composition comprising the immunogenic protein and an immunologically acceptable carrier, diluent or excipient is described. Furthermore, a vaccine comprising the immunogenic protein is described. Also described are an isolated nucleic acid that encodes the immunogenic protein and a genetic construct comprising that isolated nucleic acid. Further, a host cell comprising the genetic construct is described. A method of immunizing against | 06-30-2011 |
20100297623 | NOVEL HUMAN ssDNA BINDING PROTEINS AND METHODS OF CANCER DIAGNOSIS - A method for detecting transformed cells or tumour cells, a method for diagnosing or prognosing cancer or for assessing a predisposition to cancer, and kits for use in the methods are disclosed. The methods particularly involve the detection of overexpression of an ssDNA binding protein (SSB) or polypeptide comprising the following amino acid sequence: FX | 11-25-2010 |
20100183647 | Novel human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor - The present invention provides CTL epitope peptides and polyepitope peptides from 14 distinct antigens of human cytomegalovirus (HCMV) that are restricted through HLA the must commonly prevalent class I alleles in different ethnic populations of the world. These epitopes provide an important platform for CTL epitope-based vaccines against HCMV. The present invention further provides vaccine compositions comprising the subject epitope and polyepitope peptides and methods for vaccination of humans and for the adoptive transfer of HCMV-specific T cells to human subjects. The present invention further provides reagents and methods for determining the HCMV status or level of HCMV-specific immunity of a subject. | 07-22-2010 |
20100092500 | NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND B-CELL EPITOPES - The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope. | 04-15-2010 |
20090304660 | G-CSF DERIVATIVE FOR INDUCING IMMUNOLOGICAL TOLERANCE - The invention relates to a method for inducing immunological tolerance, in particular transplantation tolerance, by administering a G-CSF derivative or biologically active fragment, homolog, or variant thereof, in particular peg-G-CSF, to a donor cell or a transplantation donor. The invention also relates to expanding and stimulating selected donor cells by administering a G-CSF derivative, preferably peg-G-CSF. The donor cells are preferably granulocyte-monocyte precursor cells and IL-10 secreting T cells. | 12-10-2009 |
20080255044 | Method of treatment - The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated. | 10-16-2008 |